Key Documents

View All Documentation

Danazol

Name: Danazol
Brand: SIGMA

≥98%

Synonym(s):

17β-Hydroxy-2,4,17α-pregnadien-20-yno[2,3-d]isoxazole, 2,4,17α-Pregnadien-20-yno[2,3-d]isoxazol-17-ol

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₇NO₂

CAS Number:

17230-88-5

Molecular Weight:

337.46

NACRES:

NA.77

PubChem Substance ID:

24277708

UNSPSC Code:

51111800

EC Number:

241-270-1

MDL number:

MFCD00056838

Assay:

≥98%

Form:

powder

Quality level:

200

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Quality Level

200

assay

≥98%

form

powder

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada

SMILES string

CC12Cc3cnoc3C=C1CCC4C2CCC5(C)C4CC[C@@]5(O)C#C

InChI

1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16?,17?,18?,20?,21?,22-/m0/s1

InChI key

POZRVZJJTULAOH-ZIKCMSSPSA-N

Description

Biochem/physiol Actions

Danazol is a weak androgen; anterior pituitary suppressant.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	1162501	SML2344	G5168
Sigma-Aldrich D8399 Danazol	USP 1162501 Danazol	Sigma-Aldrich SML2344 SJB3-019A	Sigma-Aldrich G5168 (Z)-Guggulsterone
form powder	form -	form powder	form powder
assay ≥98%	assay -	assay ≥98% (HPLC)	assay ≥89% (HPLC)
drug control regulated under CDSA - not available from Sigma-Aldrich Canada	drug control regulated under CDSA - not available from Sigma-Aldrich Canada	drug control -	drug control -
Quality Level 200	Quality Level -	Quality Level -	Quality Level 200

Still not finding the right product?

Explore all of our products under Danazol

pictograms

GHS08,GHS07

signalword

Warning

hcodes

H312 + H332,H361

pcodes

P202 - P261 - P280 - P302 + P352 + P312 - P304 + P340 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis.

Johannes Parmentier et al.

International journal of pharmaceutics, 437(1-2), 253-263 (2012-09-04)

Liposomes are generally well tolerated drug delivery systems with a potential use for the oral route. However, little is known about the fate of liposomes during exposure to the conditions in the gastro-intestinal tract (GIT). To gain a better understanding

Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.

Hywel D Williams et al.

Journal of pharmaceutical sciences, 101(9), 3360-3380 (2012-05-31)

The Lipid Formulation Classification System Consortium is an industry-academia collaboration, established to develop standardized in vitro methods for the assessment of lipid-based formulations (LBFs). In this first publication, baseline conditions for the conduct of digestion tests are suggested and a

Danazol for unexplained subfertility.

E Hughes et al.

The Cochrane database of systematic reviews, (1)(1), CD000069-CD000069 (2007-01-27)

The synthetic androgen Danazol, was developed in the 1970's as a treatment for endometriosis. Its use was soon advocated in women with unexplained subfertility. Two randomised trials were subsequently conducted to assess the effectiveness of danazol in this population. The

Key Documents

Skip To

Danazol

≥98%

Select a Size

About This Item

Quality Level

assay

form

drug control

SMILES string

InChI

InChI key

Biochem/physiol Actions

Features and Benefits

Packaging

Compare Similar Items

This Item

Still not finding the right product?

Safety Information

pictograms

signalword

hcodes

pcodes

Hazard Classifications

Storage Class

wgk

flash_point_f

flash_point_c

ppe

Documentation

Certificates of Analysis (COA)

Already Own This Product?

Peer Reviewed Papers

Questions

Reviews

Active Filters